분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-11-03 18:01:30 , Hit : 362
 Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes


GEN News Highlights
More »
November 2, 2018
https://www.genengnews.com/gen-news-highlights/novel-two-pronged-method-targets-cancer-cells-telomerase-and-chromosomes/81256390

Scientists hope to identify cancer drugs that work in a two-pronged approach—by inducing errors when cancer cells divide packages of their DNA, known as chromosomes, as seen here, as well as inhibiting a key protein in cancer cells, known as telomerase [Mar Carmena and Emma Peat]

An international team of researchers has developed a new technique for identifying potential cancer drugs that could streamline the development of therapies. The team devised a way to screen potential drug compounds to select those that interfere with tumor cells in two ways.

Their study (“Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy”), published in Cancer Research, seeks to build on an existing method of finding drugs that target telomerase. Scientists hope to identify drugs that not only inhibit this protein but also induce errors when cancer cells divide their chromosomes to form new cells.

An attack on two fronts could prevent cancerous cells from growing and, therefore, kill tumors, say the researchers.

“The targeting of telomerase and telomere maintenance mechanisms represents a promising therapeutic approach for various types of cancer. In this work, we designed a new protocol to screen for and rank the efficacy of compounds specifically targeting telomeres and telomerase. This approach used two isogenic cell lines containing a circular human artificial chromosome (HAC, lacking telomeres) and a linear HAC (containing telomeres) marked with the EGFP transgene; compounds that target telomerase or telomeres should preferentially induce loss of the linear HAC but not the circular HAC,” wrote the investigators.

“Our assay allowed quantification of chromosome loss by routine flow cytometry. We applied this dual-HAC assay to rank a set of known and newly developed compounds, including G-quadruplex (G4) ligands. Among the latter group, two compounds, Cu-ttpy and Pt-ttpy, induced a high rate of linear HAC loss with no significant effect on the mitotic stability of a circular HAC. Analysis of the mitotic phenotypes induced by these drugs revealed an elevated rate of chromatin bridges in late mitosis and cytokinesis as well as UFB (ultrafine bridges). Chromosome loss after Pt-ttpy or Cu-ttpy treatment correlated with the induction of telomere-associated DNA damage. Overall, this platform enables identification and ranking of compounds that greatly increase chromosome mis-segregation rates as a result of telomere dysfunction and may expedite the development of new therapeutic strategies for cancer treatment.”

Researchers at the University of Edinburgh, the Institute Curie in Paris, the U.S. National Cancer Institute, and the Kazusa DNA Institute of Japan tested drug compounds using artificial human chromosomes with in-built fluorescent markers. This allowed the team to detect when and how often drug treatment caused the loss of chromosomes.

Drugs identified in this way were then tested in different types of cancer cells to investigate exactly how they were able to disrupt chromosome division at a high rate. Researchers hope these newly identified drugs can inform the development of more effective therapies.

"Our approach enables the selection of drug compounds that disrupt normal division of cancer cells,” said William C Earnshaw, Ph.D., professor of chromosome dynamics at the University of Edinburgh's School of Biological Sciences, who participated in the study. “Our hope is that this can result in the development of more effective therapies to target tumors."

"We hope our two-pronged approach can prove useful in targeting a range of cancers using newly selected, more efficient drugs," added Mar Carmena, Ph.D., senior research associate at the University of Edinburgh's School of Biological Sciences, who also took part in the study.








1267   [바이오토픽] CRISPR 특허전쟁 항소심, 브로드 연구소 승리  이성욱 2018/09/11 245
1266   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 260
1265   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 265
1264   Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 270
1263   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 284
1262   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 288
1261   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 294
1260   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 297
1259   Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements  이성욱 2018/07/17 299
1258   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 330
1257   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 331
1256   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 348
1255   RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches  이성욱 2018/10/18 352
1254   Keytruda Gets FDA Approval for Hepatocellular Carcinoma  이성욱 2018/11/14 354
1253   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 355
  Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes  이성욱 2018/11/03 362
1251   Immunotherapy Pioneers Take 2018 Nobel Prize  이성욱 2018/10/02 367
1250   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 371
1249   Checkpoint Inhibitor Generated by Synthetic DNA in Vivo  이성욱 2018/10/06 374
1248   분자수준 인체 간세포 지도 처음 작성  이성욱 2018/10/24 377

1 [2][3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN